A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies.
about
Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trialsA modified toxicity probability interval method for dose-finding trials.Novel methods and technologies for 21st-century clinical trials: a review.Approaches to modernize the combination drug development paradigmAplusB: A Web Application for Investigating A + B Designs for Phase I Cancer Clinical TrialsPerformance of toxicity probability interval based designs in contrast to the continual reassessment method.Implementation of adaptive methods in early-phase clinical trials.A comparative study of adaptive dose-finding designs for phase I oncology trials of combination therapies.Seamless Phase I/II Adaptive Design for Oncology Trials of Molecularly Targeted Agents.Performance of two-stage continual reassessment method relative to an optimal benchmarkDose-finding design for multi-drug combinations.Continual Reassessment and Related Dose-Finding DesignsContinual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 data.Adaptive dose-finding studies: a review of model-guided phase I clinical trials.Efficiency of new dose escalation designs in dose-finding phase I trials of molecularly targeted agents.Challenges of clinical trial design for targeted agents against pediatric leukemias.Evaluating the performance of copula models in phase I-II clinical trials under model misspecification.Incorporating lower grade toxicity information into dose finding designs.American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment.New considerations in the design of clinical trials for amyotrophic lateral sclerosisThe impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials.Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials.Interplay of priors and skeletons in two-stage continual reassessment method.Principles of dose finding studies in cancer: a comparison of trial designs.Scientific Review of Phase I Protocols With Novel Dose-Escalation Designs: How Much Information Is Needed?Dose expansion cohorts in Phase I trials.Phase 1 trial design: is 3 + 3 the best?Clinical trials of interventional oncology-moving from efficacy to outcomes.Embracing model-based designs for dose-finding trials.Small-sample behavior of novel phase I cancer trial designs.Integrating the escalation and dose expansion studies into a unified Phase I clinical trial.Estimating the dose-toxicity curve in completed phase I studies.Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.Design considerations for dose-expansion cohorts in phase I trialsContinual reassessment and related designs in dose-finding studiesAn approach to meta-analysis of dose-finding studies.Posterior maximization and averaging for Bayesian working model choice in the continual reassessment method.An adaptive model switching approach for phase I dose-finding trials.The Randomized CRM: An Approach to Overcoming the Long-Memory Property of the CRM.
P2860
Q26823418-DBF79B3D-3FDD-4B30-BC6B-D27EE53404F7Q27023178-DE10C221-3ECC-4C6E-BCF7-6D4E70945B33Q27323581-EBCDA060-7A42-4079-B4F2-E406F0631547Q27345820-BE793FE0-B530-443B-BEE0-30A903639AEEQ28072074-331EC0FD-D402-44D2-B1C8-70CA67D63D87Q28552571-D3F90639-0949-4079-8B01-995B272F902AQ30276332-1A29D8B8-5ECB-4ADA-A9F8-355414DE287EQ30277243-852D53C7-FAAB-44B9-9940-66FF3809A7C1Q30299951-E5C78FE7-2A71-4D16-A59A-ED49FE6C177BQ30371414-BBCFA979-BF6D-4446-B6BD-ED4BFF0ADF38Q30407451-3413438D-B9E6-49E1-9D80-0D08101BB327Q30424392-CC4AEFE2-9137-46B5-B14C-7047F6C4349BQ30431500-23B156AA-6EF5-4581-922D-92F600862E4FQ31125934-DE5129F7-9AD6-470E-8346-8CDB0221EA58Q34001009-C383FE0D-F642-4AF2-A09A-C7456E31B166Q34516049-437B2FE4-736D-46A6-9C73-D9300CDC11C5Q34839887-1BC726E7-EF18-4A73-8A08-0E84E4293C5AQ35147308-2010FC7C-1AAA-49DF-ADB9-3E332DC4B2A2Q35800784-1E153156-D0D9-4B59-947F-F8CE1E1FE143Q35894574-C3C625F8-A700-458A-B91B-7B3514F20BD9Q35910744-D6173829-CF0E-4CCB-8223-A1478504BFF5Q36295897-7ADE0C9D-ED52-4B88-9BFC-C72EE806B39CQ36326389-FA91756D-1F5F-486C-991D-9DF0594A573AQ36513919-03607407-3E77-435A-9B4C-CDFDAA1D137CQ36795347-3139721D-8FF1-4A5F-940F-4325BE409A3DQ37129865-D7F8B078-B04B-4E7D-A19E-3F5D8ADA9318Q37158298-0794640F-1955-4EFF-A63A-623B7075F717Q38222466-7BB7168C-A3FB-4AFC-A5FB-18DE74A7A2AFQ38285540-D8AA1C7A-189C-4A5D-B810-BFE71309DE22Q38700689-9D43B151-D15D-410A-AA42-E6730D5E9DFAQ39479987-A84D9FDA-04C3-4EC0-936C-574F7EBD6ED8Q39620076-15B761E8-12A3-4749-AA25-9E89BE0DAF0DQ40764278-3A1909E2-42C9-47C3-8D33-233177BC7324Q41282610-5587456F-3E99-47D2-AB3D-DD0502B2AFC5Q41895594-E6C50A00-C172-4F6E-9A86-9249BE6BDA45Q42172755-14034FF2-3C11-4364-A518-F3DAB11F92EFQ44067693-CBBCCCBA-56C6-4954-BBAB-4026B16C864DQ45023344-207E212E-AC88-41F8-B4C1-DD6248ED0F46Q45698393-EAD39190-EEEC-4F27-A001-4601260581CAQ47915807-5A38F9EF-749F-475D-B6C5-A7982089AAAC
P2860
A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
A comprehensive comparison of ...... Phase I dose-finding studies.
@en
type
label
A comprehensive comparison of ...... Phase I dose-finding studies.
@en
prefLabel
A comprehensive comparison of ...... Phase I dose-finding studies.
@en
P2093
P2860
P356
P1433
P1476
A comprehensive comparison of ...... Phase I dose-finding studies.
@en
P2093
Alexia Iasonos
Andrew S Wilton
David R Spriggs
Elyn R Riedel
Venkatraman E Seshan
P2860
P304
P356
10.1177/1740774508096474
P577
2008-01-01T00:00:00Z